first
Notability audit
from €4903–5 days
- written verdict on every source
- "passes / too early" verdict
- credited if you go on within a month
Wikipedia for healthcare · notability index 2026
In healthcare, pharma and wellness, 51% of topics in our 2018–2026 assessments have low notability confidence, 49% medium, none high. A page is possible where independent press has written about the company itself, so we check the sources first and only then write.
// 51% low confidence — our assessment pipeline, not the market · prices from the 11.2026 price list · paid edits are disclosed in WikiBusines' name
sources the scanner goes throughindependent significant: 3 of 6
Company N is a medical device manufacturer for diagnostics, founded in 2016.[1] It makes portable analyzers for laboratories.[2]
passes: 3 significant independent
Company N is a pharmaceutical R&D company developing therapies for rare diseases.[1] One of its drugs is in clinical trials.[2]
borderline: 2 significant independent
Company N is a network of outpatient clinics, founded in 2012.[1] It has several branches in large cities.
does not pass: 1 significant independent
Why a page
A company page is read by the people who make decisions: patients, doctors, partners and investors. Below is what it gives you and what we do with the page at each stage.
Patients, doctors and partners check a clinic or company through search. A neutral article with sources gives them a verified description instead of advertising.
2Approvals, trials, deals and ownership changes are described neutrally and with sources, instead of being scattered across press releases.
3ChatGPT, Gemini and Perplexity rely on encyclopedic sources for medical queries, and Google shows a knowledge panel about the company.
4Rumors, outdated facts and confusion with similarly named companies are corrected in an article that is updated with sources.
from €2,400 English · 4–5 weeks
A neutral article about a company or institution, with clinical and regulatory facts only from reliable sources. 90 days of monitoring and guarantee.
€700–€1,900 2–3 weeks
New funding rounds, licenses, products, leadership, approvals and trial results. We remove outdated content, with sources.
from €720/year 12 months of guarantee
Monitoring of changes and vandalism: unsourced medical claims do not stay in the article for long.
Paid edits are always disclosed on Wikipedia in WikiBusines' name. Page protection is applied only by Wikipedia administrators.
01Does it pass
Wikipedia assesses a company under WP:NCORP: it needs several significant, independent and reliable sources in which the company is the subject. Traffic, investment or the number of patients or clients prove nothing on their own. WP:MEDRS applies separately, but it governs medical claims in the text of the article, not the company's notability.
✓Counts
“…the regulator has approved Company N's device, which allows patients' condition to be monitored at home, the outlet reported…”
editorial article · independent outlet✗Does not count
“We were named clinic of the year, and thousands of patients thank our team!”
own website · advertising, not a source≈Gray area
“Registry entry: trial started, sponsor — Company N.”
primary record · for facts onlyWikiBusines expert estimate, 11.2026, based on which sources usually exist in the niche. It is not part of the dataset and not a statistic. Click a niche to highlight the closest profile in the top block.
counts: Journal publications of study results, clinical trial registry entries, business press on deals and regulator decisions.
does not count: Press releases about the start of a stage, investor presentations and sponsored reviews.
counts: Journalistic pieces on the network, its growth, deals or cases; medical press when the clinic itself is the subject.
does not count: Patient reviews, doctor rankings and "best clinics" roundups.
counts: Publications on clinical trials of the device, regulator decisions and reviews in the medical and technology press.
does not count: Equipment catalogs, demo videos and press releases about certification.
counts: Business and medical press on the service, studies of its effectiveness and regulator decisions.
does not count: App store pages, user reviews and affiliate reviews.
counts: Investigations and critical pieces on the supplements market or a network that name the company; independent clinical studies of the product.
does not count: Advertorial reviews, influencer tips, reviews and store pages.
counts: Press pieces on a network or a high-profile case; scientific publications involving the clinic.
does not count: Before-and-after photos, reviews, doctor roundups and paid clinic rankings.
01bSegments
The notability index groups the whole industry together, but a clinic, a pharma developer and a supplement maker have different sources and different risks. In all three, WP:MEDRS applies to medical claims in the article, not to the company's notability.
✓What usually counts
Journalistic pieces on a network or institution: growth, deals, court and regulatory cases. Medical and business press when the clinic itself is the subject. A regulator decision on a telemedicine service that the press wrote about.
✗What does not count
Patient reviews, doctor rankings, "best clinics" roundups. Press releases about new equipment and new branches.
!Main risk in the article
Treatment promises and patient reviews. "Certified" or "licensed" without a document from the registry.
%Chance by index
✓What usually counts
Business press on licensing deals, mergers and regulator decisions. Peer-reviewed publications and trial registry entries confirm facts, but notability comes from press coverage of the company itself.
✗What does not count
Press releases about the start of stages, investor presentations, sponsored reviews. A ClinicalTrials.gov entry: it is created by the company itself, so it is a primary source.
!Main risk in the article
Medical claims without peer-reviewed reviews and guidelines (WP:MEDRS): efficacy taken from a press release or a single study.
%Chance by index
✓What usually counts
Investigations and critical pieces on the supplements market or a network that name the company directly. Independent clinical studies of the product as support for claims.
✗What does not count
Advertorial reviews, influencer tips, reviews, store pages and "best" product roundups.
!Main risk in the article
Health claims without evidence and a promotional tone. The article reads like a promo, not a description of the company.
%Chance by index
Niche ratingalmost neverdepends on sourcesrealisticWikiBusines expert estimate 11.2026, not a dataset
02Sources
Tier and WP:RSP status come from our media list. Peer-reviewed journals sit in the trade group: they support medical claims in the article (WP:MEDRS) but do not prove the company's own notability. What counts is the piece, not the outlet as a whole.
TierTier 1 · reliableTier 2 · with caveatsTier 3 · situationalNo consensusAvoid
WP:RSP statusgenerally reliableno consensusgenerally unreliabledeprecatedblacklistedsource category
Reutershow we count the outlet's material
✓An editorial news report or article about the company, its deal or a regulator decision.
✗A one-sentence mention and a reprinted press release.
Financial Timeshow we count the outlet's material
✓Editorial pieces and investigations about the company or a market in which it is named.
✗Sponsored content and columns by outside authors.
Bloomberg Newshow we count the outlet's material
✓News and analysis about the company or a deal.
✗Bloomberg profiles: profiles built from company data; in the list they are a separate row with a lower tier.
The Wall Street Journalhow we count the outlet's material
✓An editorial article about the company, its product or a deal.
✗A mention in a market overview, a comment or an author's column.
Forbes (staff writers)how we count the outlet's material
✓A piece by a staff writer about the company, keeping the "no consensus" status in mind.
✗Forbes Contributor: columns by outside authors fall under "avoid" in the list.
PR Newswirehow we count the outlet's material
✓Nothing: it is a press release distribution service without editorial review.
✗A press release does not become an independent source, even when a large site reprints it.
JAMApeer-reviewed journal · for medical claims
✓Peer-reviewed articles and reviews as support for medical claims in the text (WP:MEDRS).
✗As proof of the company's notability: a study of a drug or device is not coverage of the company itself.
Academic journalspeer-reviewed journals · for medical claims
✓Systematic reviews and meta-analyses as support for clinical claims.
✗A single company-sponsored study does not prove notability.
Industry trade presstrade press with named editors
✓Editorial pieces about the company, its product or a deal.
✗Press releases, affiliate roundups, executive interviews and association white papers.
Dotdash Meredith (Verywell)how we count the outlet's material
✓General facts only, and with caution: there is no consensus on its reliability.
✗"Best clinics and drugs" roundups and advertorial reviews.
Healthlineblacklisted on WP:RSP
✓Nothing: the pieces are written mostly by freelancers without relevant expertise.
✗Suitable neither for notability nor for medical claims.
Natural Newsblacklisted on WP:RSP
✓Nothing: the site is blacklisted and is not cited.
✗A link to it in an article about a medical company will immediately raise a reviewer's question.
BBChow we count the outlet's material
✓An editorial report or investigation about the company or network.
✗A mention in a program or overview where the company is not the subject.
The Guardianhow we count the outlet's material
✓Editorial pieces and investigations about the company.
✗Blogs and opinion columns: these are separate sources with lower weight.
The Washington Posthow we count the outlet's material
✓Editorial pieces about a company or the market in the United States.
✗Affiliate and sponsored content.
Los Angeles Timeshow we count the outlet's material
✓Editorial pieces about a company, a deal or a market.
✗Advertising and sponsored sections.
The Timeshow we count the outlet's material
✓Editorial pieces and investigations about the company.
✗Advertising, sponsored content and authors' blogs.
Daily Mail / MailOnlinedeprecated on WP:RSP
✓Nothing: the site is marked deprecated because of weak fact-checking.
✗A link to it does not help the page and only raises a reviewer's question.
This is how a reviewer reads every link. For medical material there is a third outcome: the source is fine for facts in the text but does not prove notability.
Company N received regulator clearance for its device
editorial article · staff writer byline
Counts as an independent sourcepassed 5 of 5
Company N announced certification of a new device
"news" · text matches the company's press release
Does not count A retold press release is not independent coverage.passed 3 of 5
Results of a study of Company N's device: a randomized trial
peer-reviewed publication · about the device, not the company
Facts only Confirms a medical claim (WP:MEDRS) but does not prove the company's notability.passed 4 of 5
03Risks
A medical topic is watched by an active community of editors. They check every clinical claim against WP:MEDRS: it takes peer-reviewed reviews and guidelines from recognized health bodies, not patient or clinic experience. Below, a reviewer places a tag, and we show how we would rewrite it.
Drug N
Drug N effectively treats diabetes, as our clinic's experience confirms.
In a phase 3 trial, drug N was compared with placebo; the results were published in a peer-reviewed journal [1], for the efficacy assessment see the reviews [2].
what is wrongThe efficacy claim rests on the clinic's experience. For medicine that is not a source.
how we write itOnly the trial facts with a peer-reviewed source; efficacy is taken from reviews and guidelines.
WP:MEDRSno treatment promises
Device N
Device N received regulator approval.
The company has filed an application for clearance; as of the publication date there is no regulator decision in the registry [1].
what is wrongA filing was presented as clearance. A pending 510(k) is not clearance, and a De Novo request is not an approval.
how we write itWe name the stage precisely and link to the regulator's registry entry, not to a press release.
registry entrystage without gloss
Company N
Biotech company N is developing a therapy and has started phase 1 trials [press release].
We submit the article once independent press or peer-reviewed data appear; until then, a Wikidata entry.
what is wrongPreclinical stage or phase 1 only, with no published data: there are usually no independent sources yet.
how we write itWe say honestly "too early" and suggest Wikidata and alternative wikis until a source base appears.
Wikidata€490 audit
Company N
Company N is the winner of the "Best Clinic of the Year" award and a leader in its segment.
An independent outlet wrote about the award [1]; the award itself does not confer notability, so it is one fact among others.
what is wrongThe award is presented as proof of notability, and "leader" has no source.
how we write itWe mention an award only when independent press wrote about it; we do not use judgments like "leader".
neutral toneno "leader"
Clinic N
Thousands of patients thank the clinic, and its equipment is certified to an international standard.
The clinic holds a license, number in the regulator's registry [1]; we do not quote patient reviews in the article.
what is wrongPatient reviews are not a source, and "certified" without a document from the body that issued the certificate cannot be verified.
how we write itLicenses and certificates only from a registry or a document; no patient photos or reviews.
from a document onlyno reviews
04Article
A neutral description: what the company is, which products or services it has, which regulatory and scientific facts exist, and what has been written about it, including critically. Every claim has a footnote to an independent source. There are no clinical promises, price tags or reviews in it.
Company N
From Wikipedia, the free encyclopedia
Company N is a medical device manufacturer for diagnostics[1].
Historyfootnote [1]
When and why the company was founded, key stages of growth, deals and ownership changes.
✓The basis is independent editorial pieces about the company.
✗The company's own website and press releases are good only for dates and names.
Products and servicesfootnote [3]
What exactly the company makes or provides, for whom, in which countries. We describe, we do not advertise.
✓Descriptions in business and trade outlets.
✗Slogans, price tags and unsourced comparisons with competitors.
Science and regulatorfootnotes [2], [4]
Regulator decisions, clinical trials, publications. Approvals are presented as facts, not as proof of notability.
✓A registry entry for approvals; peer-reviewed reviews for medical claims (WP:MEDRS).
✗Treatment promises and efficacy conclusions taken from a press release.
Criticism and incidentsfootnote [5]
If independent press wrote about cases, product recalls or complaints, they go into the article: a neutral article does not consist of praise alone.
✓Editorial pieces and regulator decisions.
✗Rumors, anonymous reviews and social media posts.
Sourceslist of footnotes
The scanner checks every footnote: independent, editorial, substantive. We replace weak links before submission.
✓Several different outlets, not five links to one.
✗Press releases, Crunchbase, directories and "best of" roundups.
What is left outcut from the draft
05Process
The overall process is the same as for any company. What differs in healthcare is how we handle clinical claims and registries.
We go through the publications about the company against five checks and give a written verdict.
In healthcare: peer-reviewed reviews are collected separately, as support for facts, not as proof of notability.We write a draft with footnotes and disclose paid editing on Wikipedia in WikiBusines' name.
In healthcare: clinical claims only with a peer-reviewed source, no treatment promises or reviews.We submit the draft for review to English Wikipedia or another language edition.
In healthcare: FDA, EMA and NHS entries are presented as facts about approvals, not as proof of notability.A reviewer may ask for sources or cut sections. We respond within the rules.
In healthcare: weak claims are removed, not defended.We follow edits and discussion. Protection is applied only by Wikipedia administrators.
In healthcare: pages on such topics are edited more often, so annual support fits here.monitoringsupportguarantee80% refund if a published page cannot be defended after 3 attempts within this window
06Pricing
A medical topic does not cost more. The price depends on the language edition and the scope of work, not on the industry.
first
from €4903–5 days
English Wikipedia
from €2,4004–5 weeks
Ukrainian, French, Spanish
from €1,500per language edition
Guarantee: 80% refund if a published page cannot be defended after 3 attempts within the 90-day window. Guarantee terms →
07Questions and answers
It is an important fact for the article, but not notability on its own. You need independent press pieces about the company or the device, or significant coverage in peer-reviewed literature. A registry entry confirms the approval, and what has been written about it proves notability.
No, not by itself. Peer-reviewed publications support the medical claims in the article (WP:MEDRS), but a study of a product is not significant coverage of the company. Notability comes from independent pieces about the company itself, while publications make the article more accurate.
Only if independent press described the partnership. Joint announcements and statements by the parties are primary sources: they confirm the fact of the collaboration, not notability.
Editorial pieces from trade and business outlets with named editors, for example STAT, MedTech Dive, Fierce Healthcare. Regulator registries (FDA, EMA, NHS) and PubMed confirm facts and medical claims, but not notability. A ClinicalTrials.gov entry is created by the company itself, so it is a primary source. Crunchbase has deprecated status on WP:RSP. Association white papers, conference materials and letters of recommendation do not count.
Licensing deals are often covered by trade outlets such as Fierce Pharma and BioPharma Dive and by the national business press. If the pieces are in-depth and editorial, they may be enough as a basis for an article. Before the deal, without independent publications, it is much harder, and an audit will show the real picture.
Technically yes, but we do not recommend it. In this industry 51% of topics have low confidence. The first assessment is free and takes about 10 minutes; if the case is unclear, a paid audit (from €490, 3–5 days) shows whether there is anything to submit, and its cost is credited to the project if you go on within one month.
The index describes the industry, not your company: exceptions happen. The audit will show which independent publications are missing. Until they exist, there are fallback routes: an entry in Wikidata, pages on alternative wikis (Wikitia, EverybodyWiki) and systematic work on media publications.
Notability audit from €490: 3–5 days and a written verdict on every source. The cost is credited to the project if you decide to go on within one month. If the answer is "too early", we will say so.